ArticleBMC cancer2025
Chidamide impedes glycolysis but increases ferroptosis and cisplatin sensitivity of lung cancer cells through downregulating USP35.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Stage-Specific Regulation of Ubiquitination Modifications and Prospects for Targeted Therapy in Triple-Negative Breast Cancer.Oncology research · 2026Review
- The deubiquitinase USP35: from an oncogenic hub to a therapeutic target in human cancers.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundChidamide is a histone deacetylase inhibitor playing an anti-cancer role in several cancers. However, the function of chidamide in lung cancer remains to be further elucidated. This study was designed to explore the regulation of chidamide in glycolysis, ferroptosis, and chemosensitivity of cisplatin (DDP) in lung cancer, as well as its action mechanism associated with ubiquitin-specific protease 35 (USP35).
methodsCell viability and half maximal inhibitory concentration were examined using Cell Counting Kit-8 assay. Glycolysis metabolism was assessed through glucose uptake, lactate generation, and intercellular ATP level. Ferroptosis analysis was performed by detection of reactive oxygen species, glutathione and Fe2+ level. DDP sensitivity was evaluated by colony formation assay and flow cytometry. The protein expression was measured by Western blotting. The function of chidamide in mice was investigated using tumor xenograft assay.
resultsLung cancer cell viability was decreased by chidamide. Chidamide resulted in glycolysis inhibition, ferroptosis promotion, and DDP sensitivity elevation of lung cancer cells. Chidamide could bind to USP35 and reduced its protein expression in lung cancer. The effects of chidamide on glycolysis, ferroptosis and DDP sensitivity were attributed to the downregulation of USP35. Chidamide reduced tumor growth in mice, and enhanced the sensitivity of tumors to DDP.
conclusionThese findings proved that chidamide blocked lung cancer cell development and elevated DDP sensitivity via targeting USP35.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.